Using nerve monitoring to help protect nerves during breast cancer lymph node surgery
Official title: Feasibility of Using Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) to Provide Early Identification and Protection of the Intercostalbrachial Nerve (ICBN), Medial Branch Cutaneous Nerve (MBCN), and Their Branches
Run by University of Cincinnati · NCT07528638 · Data updated 2026-11-12
This study tests whether intraoperative nerve monitoring and bipolar electrocautery during axillary lymph node dissection can help identify and preserve nerves to reduce post-surgical neuropathic pain.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 6 (estimated) |
| Sponsor | University of Cincinnati Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Cincinnati, Ohio) |
| Status | Recruiting |
| Started | June 29, 2026 |
| Main results expected | June 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | July 1, 2026 |
| Trial ID | NCT07528638 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18-70 with pathologically confirmed breast cancer scheduled for ALND who have no prior axillary surgery or conditions that affect nerves.
✕Probably not a fit
Patients with pre-existing neuropathy, prior extensive axillary surgery, or factors that preclude safe use of neuromonitoring may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants are adults with breast cancer undergoing axillary lymph node dissection. The trial uses intraoperative neuromonitoring, including somatosensory evoked potentials and direct electrical stimulation, and replaces monopolar with bipolar cautery to help locate and protect nerves such as the ICBN and MBCN. The goal is to see if these techniques improve early nerve identification and nerve preservation during surgery. This is a feasibility/interventional assessment conducted at the University of Cincinnati with collaboration from Evokes Neuromonitoring. The study outlines parameters for reliably identifying nerves and minimizing heat spread to reduce neuropathic pain risk.
Why it matters
Potential benefit: If successful, patients may experience lower risk of neuropathic pain after ALND and related chronic discomfort.
How similar studies have gone: Preliminary data suggest nerve preservation can reduce neuropathic outcomes when nerves are locatable; this is a feasibility study building on those concepts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients ages 18-70 years old. 2. Pathologically confirmed diagnosis of breast cancer. 3. Undergoing ALND by one of the breast surgeon Sub-Investigators on this study. Exclusion Criteria: 1. Patients having any previous axillary surgery other than percutaneous breast biopsy and/or SLNB. 2. Prior breast radiation with neuropathy clearly developing after radiation. 3. Patients who have undergone prior chemotherapy and developed post-chemotherapy neuropathy prior to ALND. 4. Patients with any pre-existing neurological conditions affecting nerves, such as neuropathy (peripheral neuropathy, neuropathic pain or nerve injury to upper extremity). 5. Patients taking medications that are known to modify neuropathic pain (eg, gabapentin, pregabalin, duloxetine, venlafaxine, lidocaine patches, capsaicin, opioids, tramadol, NMDA receptor antagonists, clonidine, cannabis, botox). 6. Patients with prior spinal surgery or spinal pathology (cervical spinal stenosis or cervical radiculopathy). 7. Patients with limb-dysfunction. 8. Patients with demyelinating disease. 9. Patients with significant co-morbidities (clotting disorders on anticoagulation, cardiac issues, other conditions that could impact long-term follow-up). 10. Patients that present with pre-operative breast, arm or chest pain ipsilateral to anticipated ALND. 11. Patients who have had prior procedures where IONM failed intraoperatively. 12. Presence of parietal cortical lesion.
Where it's running
-
University of Cincinnati
Cincinnati, Ohio, United States Recruiting
Study contacts
- Study coordinator: UCCC Clinical Trials Office
- Email: cancer@uchealth.com
- Phone: 513-584-7698
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.